The FDA’s emergency authorization of J&J’s vaccine late last month boosted the quickening rollout of vaccines in the U.S., adding a third option in addition to shots from Pfizer and Moderna.
Yet, previous delays in manufacturing meant J&J only had 4 million doses ready to ship upon clearance, and the drugmaker only just met its target of delivering 20 million doses to the U.S. this month. Those doses were shipped from J&J’s own plant in the Netherlands, not the Emergent plant responsible for the most recent setback in supply.
